Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by MCINTOSH, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MCINTOSH, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 British Society for Rheumatology

other

THE COST OF RHEUMATOID ARTHRITIS

E. MCINTOSH

Health Services Research Unit, Department of Public Health Drew Kay Wing, Polwarth Building, Foresterhill, Aberdeen AB9 2ZD

This paper uses the Cost of Illness (COI) framework to estimate the cost of rheumatoid arthritis (RA) to society in the year 1992/93. By doing so, a clear insight is given into the many cost elements of RA treatment and monitoring. This paper estimates point prevalence rates of 2.06 and 6.94/1000 persons at risk for men and women, respectively, showing that prevalence is three times higher amongst women than men. Further to this, prevalence increases with age in both sexes, resulting in very high prevalence rates for RA amongst the elderly. The total economic impact of RA in England was estimated to be £1.256 billion in 1992, of which 52% was a result of production loss caused by RA disability.

KEY WORDS: Rheumatoid arthritis, Cost of Illness, Direct costs, Indirect costs, Economic impact


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
C. A. E. Walsh, P. Minnock, C. Slattery, N. Kennedy, F. Pang, D. J. Veale, B. Bresnihan, and O. FitzGerald
Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis
Rheumatology, July 1, 2007; 46(7): 1148 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A. Kuek, B. L Hazleman, and A. J K Ostor
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Postgrad. Med. J., April 1, 2007; 83(978): 251 - 260.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
B. Fautrel, A. E. Clarke, F. Guillemin, V. Adam, Y. St-Pierre, T. Panaritis, P. R. Fortin, H. A. Menard, C. Donaldson, and J. R. Penrod
Costs of Rheumatoid Arthritis: New Estimates from the Human Capital Method and Comparison to the Willingness-to-Pay Method
Med Decis Making, March 1, 2007; 27(2): 138 - 150.
[Abstract] [PDF]

Home page
 Occup Med (Lond)Home page
W. Burton, A. Morrison, R. Maclean, and E. Ruderman
Systematic review of studies of productivity loss due to rheumatoid arthritis
Occup. Med., January 1, 2006; 56(1): 18 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
S M M Verstappen, A Boonen, H Verkleij, J W J Bijlsma, E Buskens, J W G Jacobs, and on behalf of the Utrecht Rheumatoid Arthritis Coho
Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity
Ann Rheum Dis, December 1, 2005; 64(12): 1754 - 1760.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Kobelt, P. Lindgren, Y. Lindroth, L. Jacobson, and K. Eberhardt
Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis
Rheumatology, September 1, 2005; 44(9): 1169 - 1175.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. Hallert, M. Husberg, D. Jonsson, and T. Skogh
Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project)
Rheumatology, November 1, 2004; 43(11): 1374 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
D. James, A. Young, E. Kulinskaya, E. Knight, W. Thompson, W. Ollier, and J. Dixey
Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years
Rheumatology, March 1, 2004; 43(3): 369 - 376.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Brennan, N. Bansback, A. Reynolds, and P. Conway
Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
Rheumatology, January 1, 2004; 43(1): 62 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C.-S. Yee, A. Filer, A. Pace, K. Douglas, D. Situnayake, and I. F. Rowe
The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study
Rheumatology, July 1, 2003; 42(7): 856 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Kobelt, L. Jonsson, A. Young, and K. Eberhardt
The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study
Rheumatology, February 1, 2003; 42(2): 326 - 335.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Disability Policy StudiesHome page
P. Jacobs, D. Hailey, and A. Jones
Economic Evaluation for Assistive Technology Policy Decisions
Journal of Disability Policy Studies, January 1, 2003; 14(2): 120 - 126.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
N. J. Cooper, M. Mugford, D. P. M. Symmons, E. M. Barrett, and D. G. I. Scott
Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study
Rheumatology, July 1, 2002; 41(7): 767 - 774.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A Boonen, D van der Heijde, R Landewe, A Spoorenberg, H Schouten, M Rutten-Van Molken, F Guillemin, M Dougados, H Mielants, K de Vlam, et al.
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries
Ann Rheum Dis, May 1, 2002; 61(5): 429 - 437.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C. Dickens and F. Creed
The burden of depression in patients with rheumatoid arthritis
Rheumatology, December 1, 2001; 40(12): 1327 - 1330.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J Hill, H Bird, and S Johnson
Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial
Ann Rheum Dis, September 1, 2001; 60(9): 869 - 875.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C. M. Lambert
Medical therapy for rheumatoid arthritis--value for money?
Rheumatology, September 1, 2001; 40(9): 961 - 964.
[Full Text] [PDF]

Home page
 NEJMHome page
E. H.S. Choy and G. S. Panayi
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
N. Engl. J. Med., March 22, 2001; 344(12): 907 - 916.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
N. Sutcliffe, A. E. Clarke, R. Taylor, C. Frost, and D. A. Isenberg
Total costs and predictors of costs in patients with systemic lupus erythematosus
Rheumatology, January 1, 2001; 40(1): 37 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. M. Barrett, D. G. I. Scott, N. J. Wiles, and D. P. M. Symmons
The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study
Rheumatology, December 1, 2000; 39(12): 1403 - 1409.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
C. Gordon and A. E Clarke
Quality of life and economic evaluation in SLE clinical trials
Lupus, October 1, 1999; 8(8): 645 - 654.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.